A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine.

Nigel Fleeman Rachel Houten Marty Chaplin Sophie Beale Angela Boland Yenal Dundar Janette Greenhalgh Rui V Duarte Aditya Shenoy

Published in: BMC cancer (2019)

Lenvatinib and sorafenib are more efficacious than placebo (a proxy for best supportive care) for treating RR-DTC. Uncertainty surrounds the extent of the impact on OS and HRQoL. Lenvatinib could not reliably be compared with sorafenib. Choice of treatment is therefore likely to depend on an individual patient's circumstances.

Keyphrases

locally advanced
squamous cell carcinoma
healthcare
small cell lung cancer
multiple sclerosis
rectal cancer
neoadjuvant chemotherapy
case report
radiation therapy
pain management
magnetic resonance
computed tomography
phase iii
combination therapy
lymph node
open label
replacement therapy
study protocol